Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.

ABSTRACT: Tumor progression is facilitated immunologically by mechanisms that include low antigen expression, an absence of coimmunostimulatory signals, and the presence of regulatory T cells (Tregs), all of which act to suppress and restrict effector T cells in the tumor. It may be possible to overcome these conditions by a combination of modulatory immunotherapy agents and tumor-antigen targeting to activate and drive effective antitumor T cell responses. Here, we demonstrated that co-administration of aGITR and aPD-1 monoclonal antibodies (mAb) in combination with a peptide vaccine (Vax) in mice bearing established tumors significantly delayed tumor growth and induced complete regression in 50% of the mice. This response was associated with increased expansion and functionality of potent Ag-speci

SUBMITTER: Villarreal DO 

PROVIDER: S-EPMC5503599 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature